Women’s Health Dx
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth
May 19, 2021-The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time Read More >
EVALUATION OF HEALTH AND ECONOMIC BENEFIT OF THE PRETRM® TEST-AND-TREAT STRATEGY
TO IMPROVE MATERNAL AND INFANT HEALTH AMONG COMMERCIALLY INSURED IN THE US
May 18, 2021-Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings Read More >
Sera Prognostics Completes $100 Million Series E Financing
April 28, 2021-Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test. Read More >
WHO WE ARE
PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care. Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes. Learn about the PreTRM® Test for Risk Management.